OpenAI Launches Rosalind Biodefense — A Dedicated Life Sciences Model for Governments and Researchers 🔗

OpenAI launched Rosalind Biodefense this week, providing vetted access to GPT-Rosalind for biodefense and pandemic preparedness. Two tracks are open: one for developers building tools in epidemiological modeling and outbreak response, another for government agencies working on diagnostics and medical countermeasures. Early collaborators include Lawrence Livermore National Laboratory, Johns Hopkins Applied Physics Laboratory, and CEPI. This is a distinct program from the general GPT-Rosalind drug discovery model covered in Issue #9, with a specific government access mandate.

Sanofi Builds Its Own AI Ecosystem — and 80% of the Workforce Is Already On It 🔗

Rather than adopting external tools, Sanofi built its own generative AI platform, Concierge, now serving approximately 80% of its workforce. The next phase is agentic: AI agents handling requests in IT, procurement, and field sales preparation. Sanofi's CDO was explicit in a Fortune interview this week: controlling data and building proprietary solutions is a deliberate alternative to the SaaS model, with direct implications for every enterprise vendor serving top-tier pharma.

Solstice Raises $21 Million to Compress Pharma Marketing Review from Three Months to Ten Days 🔗

Solstice closed a $21 million Series A led by Transformation Capital. The platform targets the medical, legal, and regulatory (MLR) review cycle that delays pharma marketing campaigns by an average of three months. By pre-validating content against clinical data before it reaches the MLR review desk, Solstice reduces average review rounds from 3.2 to 1.2 and compresses timelines to approximately ten days. More than a dozen pharma companies are on the platform. Total funding is now approximately $25 million.

Novo Nordisk Targets a Two-Thirds Reduction in Drug Launch Timelines Through AI 🔗
Novo Nordisk's managing director for global business services described this week how AI integration in document preparation, safety data analysis, and commercial analytics is targeting a reduction of several months on regulatory filing timelines, historically stretching to 18 months. The Bengaluru center is executing the majority of this work across global drug launches.

The signal: Novo Nordisk is currently one of the most commercially pressured companies in pharma, with an aggressive pipeline to sustain. Disclosing specific filing timeline targets and naming a live implementation is not a PR move. It is a benchmark that other large pharma companies will now have to respond to in their own AI roadmaps.

Causaly Launches Scientific Workflows — AI Agents That Execute Expert Research Processes Consistently 🔗

Causaly launched Scientific Workflows, allowing pharma R&D teams to codify expert research methods into repeatable processes that AI agents execute end-to-end, producing traceable outputs including target assessments and safety dossiers. One early pharma deployment reported reducing manual research time by up to a month per indication assessed.

The signal: Veeva Falcon, Causaly Scientific Workflows, Sanofi Concierge — the pattern is the same. AI is entering scientific and regulatory processes at the level of workflow architecture, not conversational interfaces. The vendors who can demonstrate a full audit trail in a regulated multi-step process will define the category.

Half of Clinical Trial Professionals Name Trust as the Main Barrier to AI Adoption 🔗

A Pistoia Alliance poll at the Clinical Trials Technology Congress in London found 50% of clinical trial professionals cite trust and regulatory uncertainty as the primary barrier to AI adoption. At the same event, 42% reported early signs of ROI.

The signal: The gap is not technical. It is governance. The companies contributing to the emerging standard right now will have a structural advantage as regulators begin requiring traceability at scale.